Posted from: Wednesday, June 29, 2016 - 11:44 AM - Present

New Formulation of Jetrea Approved

June 8, 2016 – The U.S. Food and Drug Administration (FDA) approved a new formulation of Jetrea® (ocriplasmin) for the treatment of vitreomacular adhesion (VMA). Jetrea is manufactured by ThromboGenics NV. While Jetrea is already approved, the new formulation will come as an already-diluted version, eliminating the previously required preparatory dilution steps prior to injection. Jetrea is administered by intravitreal (eye) injection as a one-time dose. It is the only pharmacological treatment approved for treatment of VMA. 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Thursday, August 17, 2017 - 04:00 AM.